Jordan Douglas Secor, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intestinal Diseases | 2 | 2022 | 506 | 0.660 |
Why?
|
| Parenteral Nutrition | 3 | 2023 | 660 | 0.580 |
Why?
|
| Liver Diseases | 2 | 2022 | 1303 | 0.500 |
Why?
|
| Phospholipase D | 1 | 2011 | 71 | 0.370 |
Why?
|
| Chelating Agents | 1 | 2011 | 380 | 0.340 |
Why?
|
| Isoquinolines | 2 | 2021 | 350 | 0.320 |
Why?
|
| Mercury | 1 | 2011 | 291 | 0.310 |
Why?
|
| Endothelial Cells | 5 | 2022 | 3584 | 0.290 |
Why?
|
| Glycine | 2 | 2021 | 672 | 0.280 |
Why?
|
| Antioxidants | 2 | 2012 | 1670 | 0.270 |
Why?
|
| Phthalic Acids | 1 | 2011 | 485 | 0.260 |
Why?
|
| Soybean Oil | 2 | 2023 | 139 | 0.250 |
Why?
|
| Heparin | 2 | 2022 | 1630 | 0.230 |
Why?
|
| Fat Emulsions, Intravenous | 3 | 2023 | 314 | 0.230 |
Why?
|
| Fish Oils | 3 | 2023 | 483 | 0.220 |
Why?
|
| Serpins | 2 | 2021 | 244 | 0.210 |
Why?
|
| Fibroma | 1 | 2024 | 197 | 0.200 |
Why?
|
| Nerve Growth Factors | 2 | 2021 | 564 | 0.190 |
Why?
|
| Medical Futility | 1 | 2022 | 136 | 0.180 |
Why?
|
| Eye Proteins | 2 | 2021 | 628 | 0.180 |
Why?
|
| Heart Neoplasms | 1 | 2024 | 375 | 0.170 |
Why?
|
| Liver Failure | 1 | 2022 | 252 | 0.170 |
Why?
|
| Cholestasis | 1 | 2022 | 386 | 0.160 |
Why?
|
| Lung | 4 | 2022 | 10031 | 0.160 |
Why?
|
| Short Bowel Syndrome | 1 | 2022 | 352 | 0.150 |
Why?
|
| Fatty Liver | 1 | 2023 | 807 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2022 | 3504 | 0.130 |
Why?
|
| General Surgery | 1 | 2024 | 1722 | 0.100 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 2418 | 0.100 |
Why?
|
| Heart Ventricles | 1 | 2024 | 3831 | 0.100 |
Why?
|
| Domperidone | 1 | 2011 | 24 | 0.100 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2011 | 411 | 0.090 |
Why?
|
| Sulfhydryl Compounds | 1 | 2011 | 296 | 0.080 |
Why?
|
| Wounds and Injuries | 1 | 2022 | 2511 | 0.080 |
Why?
|
| Epithelial Cells | 1 | 2021 | 3683 | 0.080 |
Why?
|
| Health | 1 | 2012 | 397 | 0.080 |
Why?
|
| Disease | 1 | 2012 | 675 | 0.070 |
Why?
|
| Epigenomics | 1 | 2012 | 959 | 0.060 |
Why?
|
| Animals | 9 | 2023 | 168731 | 0.060 |
Why?
|
| Oxidation-Reduction | 1 | 2011 | 2218 | 0.060 |
Why?
|
| Infant | 3 | 2024 | 36363 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2024 | 5946 | 0.060 |
Why?
|
| Models, Biological | 1 | 2020 | 9441 | 0.060 |
Why?
|
| Genome | 1 | 2012 | 1752 | 0.060 |
Why?
|
| Pneumonectomy | 2 | 2021 | 1128 | 0.050 |
Why?
|
| Aorta | 1 | 2011 | 2027 | 0.050 |
Why?
|
| Emulsions | 1 | 2023 | 150 | 0.050 |
Why?
|
| Indoles | 1 | 2011 | 1832 | 0.050 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 1892 | 0.050 |
Why?
|
| Environmental Pollutants | 1 | 2011 | 1291 | 0.050 |
Why?
|
| Carbohydrates | 1 | 2023 | 386 | 0.050 |
Why?
|
| Cell Survival | 1 | 2011 | 5747 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 3717 | 0.040 |
Why?
|
| Mice | 5 | 2023 | 81792 | 0.040 |
Why?
|
| Compliance | 1 | 2020 | 100 | 0.040 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2022 | 345 | 0.040 |
Why?
|
| Picolinic Acids | 1 | 2020 | 48 | 0.040 |
Why?
|
| Total Lung Capacity | 1 | 2020 | 148 | 0.040 |
Why?
|
| Nutritional Support | 1 | 2022 | 178 | 0.040 |
Why?
|
| Hematocrit | 1 | 2021 | 621 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2012 | 3818 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 22321 | 0.040 |
Why?
|
| Program Development | 1 | 2024 | 1296 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2024 | 1884 | 0.040 |
Why?
|
| Resuscitation | 1 | 2022 | 679 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2020 | 548 | 0.040 |
Why?
|
| Pulmonary Alveoli | 1 | 2020 | 664 | 0.040 |
Why?
|
| Physical Conditioning, Animal | 1 | 2020 | 365 | 0.030 |
Why?
|
| Microcirculation | 1 | 2021 | 1280 | 0.030 |
Why?
|
| Drug Design | 1 | 2021 | 1042 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2024 | 2501 | 0.030 |
Why?
|
| Triglycerides | 1 | 2023 | 2441 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2011 | 18972 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2023 | 1806 | 0.030 |
Why?
|
| Enteral Nutrition | 1 | 2022 | 803 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2022 | 1295 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2020 | 1692 | 0.030 |
Why?
|
| Organ Size | 1 | 2020 | 2261 | 0.030 |
Why?
|
| ROC Curve | 1 | 2022 | 3618 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2021 | 23589 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2024 | 2779 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2023 | 18289 | 0.030 |
Why?
|
| Vitamins | 1 | 2022 | 1632 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2022 | 1620 | 0.030 |
Why?
|
| Exercise Test | 1 | 2021 | 2180 | 0.030 |
Why?
|
| Swine | 1 | 2022 | 5986 | 0.020 |
Why?
|
| Humans | 8 | 2024 | 765734 | 0.020 |
Why?
|
| Curriculum | 1 | 2024 | 3782 | 0.020 |
Why?
|
| Male | 6 | 2024 | 363585 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2024 | 81457 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2020 | 8279 | 0.020 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2024 | 3674 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2022 | 5343 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 10730 | 0.020 |
Why?
|
| Liver | 1 | 2023 | 7559 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2022 | 4862 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2021 | 14445 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2021 | 10428 | 0.020 |
Why?
|
| Child | 2 | 2024 | 80499 | 0.020 |
Why?
|
| Incidence | 1 | 2022 | 21478 | 0.010 |
Why?
|
| Time Factors | 1 | 2024 | 40066 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2022 | 26332 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2024 | 42468 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2024 | 65180 | 0.010 |
Why?
|
| Female | 2 | 2024 | 395961 | 0.010 |
Why?
|
| Adult | 1 | 2022 | 222974 | 0.000 |
Why?
|